Indoleamine-2,3-Dioxygenase and Interleukin-6 Associated With Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer

Oncotarget - United States
doi 10.18632/oncotarget.22253
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

RB-Pathway Disruption Is Associated With Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth With Ethyl Pyruvate

Cancer Research
Cancer ResearchOncology
2010English

Indoleamine 2,3-Dioxygenase 1 (IDO1)

Science-Business eXchange
2012English

Multiagent Neoadjuvant Chemotherapy and Tumor Response Are Associated With Improved Survival in Pancreatic Cancer

HPB
HepatologyGastroenterology
2019English

Osteopontin and Vasculogenic Mimicry Formation Are Associated With Response to Neoadjuvant Chemotherapy in Advanced Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Critical Role of Indoleamine 2,3-Dioxygenase in Tumor Resistance to Repeated Treatments With Targeted IFN

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

MRP1 but Not MDR1 Is Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Disease Markers
BiochemistryMedicineClinical BiochemistryMolecular BiologyGenetics
2013English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

Correction to “A Pt(IV) Pro-Drug Preferentially Targets Indoleamine-2,3-Dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy”

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy